If you run a head to head studies involving DuAVR and S3 , after the initial 2 results from DuAVR , you would have to call off the studies for ethical reasons. So knowing the haemodynamics of DuAVR in VIV, it would be hard for clinicians to recommend anything other than DuAVR for VIV.
- Forums
- ASX - By Stock
- AVR
- Ann: Exceptional Results in Second Valve-in-Valve Case
Ann: Exceptional Results in Second Valve-in-Valve Case, page-42
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M |
Open | High | Low | Value | Volume |
$17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 191 | $17.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$17.50 | 500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 191 | 17.150 |
1 | 1460 | 17.000 |
1 | 27 | 16.970 |
1 | 13 | 16.960 |
1 | 196 | 16.950 |
Price($) | Vol. | No. |
---|---|---|
17.500 | 500 | 1 |
17.750 | 2141 | 1 |
17.800 | 200 | 1 |
18.240 | 500 | 1 |
18.300 | 150 | 1 |
Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |